Prediction: This Healthcare Stock Could Soar by 72% in 2026

Abivax SA, currently valued at €8.74 billion, rallied roughly 1,740% last year after positive phase 3 data for obefazimod—an ulcerative colitis candidate that delivered statistically significant remission versus placebo and included 47.3% of patients who had inadequate responses to prior therapy. Reports that Eli Lilly may be preparing a €15 billion bid (about a 72% premium to Abivax’s market cap) underscore significant potential upside from an acquisition, though the story remains speculative and exposure to clinical or regulatory setbacks and the absence of a deal represent material downside risks for investors.

Analysis

Market structure: A formal bid for ABVX (rumored LLY €15bn / ~72% premium) would directly benefit ABVX shareholders and M&A advisors, while pressuring mid/large-cap immunology incumbents (e.g., ABBV) by accelerating competition in ulcerative colitis (UC) therapy. Obefazimod’s purported immune-sparing profile could expand addressable market versus JAK/TNF inhibitors, shifting pricing power toward novel mechanism entrants and compressing long-term pricing for commoditized biologics if uptake exceeds 10–20% of current UC patients within 3–5 years.

Risk assessment: Tail risks include regulatory rejection or label restrictions (20–40% probability within 12 months), safety surprises in extended exposure lowering peak sales by >50%, or a failed takeover process that triggers a >40% downmove in ABVX shares within weeks. Short-term (days-weeks) volatility will be dominated by rumor flow and potential bid announcements; medium-term (3–12 months) outcomes hinge on filings, partnering talks, and payer evidence; long-term (2–5 years) value depends on market share versus TNF/JAK incumbents and pricing concessions.

Trade implications: Primary actionable plays are merger-arbitrage and volatility-based option structures: long ABVX equity or LEAP calls with protective puts to cap downside, and a small short hedge in LLY (if bid is stock-heavy) or in ABBV to express competitive displacement. Position sizing should be tactical: 1–3% portfolio risk for speculative longs, use options to limit cash exposure, and avoid concentrated long-only stakes absent a confirmed bid within 30 days.

Contrarian angles: The market assumes a single-bidder takeout; fewer consider a competitive auction driving price above €15bn or conversely no bid and a >50% pullback if data/payer modeling disappoints. Historical parallels (MyoKardia/BMY, Seagen/SGEN) show premiums can exceed rumors in auctions; alternatively, regulatory or label limits (narrow indication) have materially reduced deal value. Prepare for binary outcomes and asymmetric payoff structures rather than buy-and-hold equities without hedges.

Key Decisions for Investors

• Establish a tactical 1–2% portfolio long in ABVX within 30 days using either (a) stock with a 20% OTM protective put (30–90 day expiry) or (b) buy Jan 2027 LEAP calls (12-month) sized to equal 1–2% risk exposure; reason: capture takeover premium/risk-on upside while capping downside to ~20%.
• If takeover rumblings intensify (formal approach or leaked exclusivity within 10 trading days), increase exposure to 2–3% and convert to merger-arbitrage: long ABVX, hedge with a 25–50% notional short in LLY (LLY) if deal expected to be stock-stock; unwind hedge on definitive agreement.
• Implement a volatility play if no bid: buy a 90-day straddle or buy calls + sell puts on ABVX around major catalyst dates (regulatory filings, meetings) to monetize event-driven IV spikes; size to 0.5–1% portfolio risk due to theta decay.
• Short selective incumbent exposure (e.g., ABBV) 0.5–1% as a pair trade (long ABVX / short ABBV) if obefazimod receives favorable label or payor evidence within 6–12 months; target pair P&L capture of 30–50% relative outperformance, stop-loss if ABVX falls >40% from entry or ABBV outperforms by 10%.
• Exit/trim rules: if no formal bid within 90 days and ABVX price falls >35% from entry, close positions or roll hedges; if a confirmed bid at ≥€15bn arrives, take profits to lock a 60–80% realized premium depending on entry timing.